AIDS Therapies (AR177)

Phase I Program for HIV Inhibitor Drug Expansion Announced

Published in AIDS Weekly, April 8th, 1996

Aronex Pharmaceuticals, Inc., The Woodlands, Texas, announced that the company expanded its clinical trial program for the HIV inhibitor AR177 to include a Phase I multiple-dose trial.

AR177, an oligonucleotide with demonstrated ability to inhibit HIV integrase, underwent a single-dose Phase I trial at San Francisco General Hospital, California, in HIV positive patients. To date, AR177 has been well tolerated with no drug-related adverse effects.

In preclinical studies, AR177 demonstrated activity against a variety of clinical isolates of HIV, including strains resistant to AZT. In the March 1996 issue of the Journal of Biological Chemistry, Nilabh...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-04-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry